Bill Gates Warns That a Next Pandemic Could Be 10 Times Worse.
Well Alrighty Then. Just as we Were Starting to Get Comfortable Sitting on a Barstool Again..
The Microsoft co-founder...
Heads Up! Big News on Stem Cells & Covid This Weekend.
Gentlemen Start Your Research Engines! Be Fast and Be Early. We Could be Looking at a "Beam Me Up Scotty" Type Vector...
Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Adding Dalrada (DFCO) $0.09 to CoronaVirus Stock Watch List.
LIVE QUOTE
Adding Dalrada (DFCO), a technology Incubator with interests in telehealth and...
Shark Tanks’ Kevin Harrington Gets Into Sanitizer Business.
Aphex BioCleanse Systems Welcomes Original Shark Tank Investor Kevin Harrington and World-Renowned Entrepreneur Mark Timm as Advisors
Citius Pharma (CTXR) Updates Shareholders.
Citius Update Stem Cell Study
Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Vaxart (VXRT) Gains $171 Million in Market Value After $9.2 Million Award from Project...
Vaxart Closes $10 Million Secondary on January 16th @0.65.
Vaxart Receives $9 Million Award from Barda on...
GeoVax (GOVX) Conference Call at 4:30 ET, the 29th.
GeoVax to Host Conference Call at 4:30 PM ET
GeoVax to Report 2023 Financial Results and Provide Corporate...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
